Ibrutinib (Ibr) for treatment of relapsed‐refractory (R/R) chronic lymphocytic leukemia (CLL): a matching‐adjusted indirect comparison of 3 randomized phase 3 trials.

Ibrutinib (Ibr) for treatment of relapsed-refractory (R/R) chronic lymphocytic leukemia (CLL): a matching-adjusted indirect comparison of 3 randomized phase 3 trials B Introduction I : i b Ibr is a standard therapy for CLL with demonstrated efficacy in first-line and R/R settings. B Methods: b Individual patient data (IPD) of Ibr-treated pts from RESONATE (NCT01578707) were separately match-adjusted to Ibr-treated arms of 1) ALPINE (NCT03734016) and 2) ELEVATE-RR (NCT02477696) for key baseline characteristics: age >=75 y, bulky disease, >=3 or >=4 prior treatments, b SB 2 sb microglobulin >3.5 mg/L, and del(11q) or del(17p). [Extracted from the article]